Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 0.04 below Provectus Biopharmaceuticals Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 410 other companies have achieved higher Quick Ratio than Provectus Biopharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 3137, from total ranking in the second quarter 2026 at 3540.

Explain Quick Ratio?
How much Cash & cash equivalents PVCT�s has?
What are PVCT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PVCT/financial-strength

https://api.csimarket.com/api/v1/companies/PVCT/fundamentals

https://api.csimarket.com/api/v1/companies/PVCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

PVCT Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-35.59 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	149.36 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.04	Subscribe	Subscribe	Subscribe	Subscribe
PVCT's Total Ranking	# 3137	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-1.54 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-84.38 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 411
Healthcare Sector	# 793
Overall Market	# 3137

Quick Ratio Statistics
High	Average	Low
41.88	5.61	0
(Sep 30 2011)		(Mar 31 2024)

Financial Statements
Provectus Biopharmaceuticals Inc 's Current Liabilities	$ 4 Millions	Visit PVCT's Balance sheet
Provectus Biopharmaceuticals Inc 's Cash & cash equivalent	$ 0 Millions	Visit PVCT's Balance sheet
Source of PVCT's Sales		Visit PVCT's Sales by Geography

Cumulative Provectus Biopharmaceuticals Inc 's Quick Ratio

PVCT's Quick Ratio for the trailling 12 Months

PVCT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-12.55 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	56.78 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.08	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4115	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-9.52 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	6.35 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to PVCT Financial Strength Comparisons >> Go to Compare PVCT Quick Ratio to its Competitors

On the trailing twelve months basis PVCT Cash & cash equivalent more than doubled by 149.36 % in Q3 2026 year on year, while Current Liabilities decreased to $4 millions, this led to increase in in Provectus Biopharmaceuticals Inc 's Quick Ratio to 0.08, Quick Ratio remained below PVCT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Provectus Biopharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2953 to 4115.

Explain Quick Ratio?
How much Cash & cash equivalents PVCT�s has?
What are PVCT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 912
Within the Market	# 4115

trailing twelve months Quick Ratio Statistics
High	Average	Low
22.41	3.75	0.01
(Sep 30 2014)		(Mar 31 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Eli Lilly And Company	0.10	$ 4,885.000 Millions	$ 46,996.000 Millions
Amneal Pharmaceuticals Inc	0.08	$ 157.399 Millions	$ 1,946.837 Millions
Propanc Biopharma Inc	0.08	$ 0.258 Millions	$ 3.240 Millions
Protagenic Therapeutics Inc new	0.07	$ 0.077 Millions	$ 1.153 Millions
Provectus Biopharmaceuticals Inc	0.04	$ 0.181 Millions	$ 4.169 Millions
Artelo Biosciences Inc	0.01	$ 0.004 Millions	$ 0.439 Millions
IMPACT BIOMEDICAL INC.	0.01	$ 0.021 Millions	$ 2.373 Millions

Date modified: 2026-11-11T13:57:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.